SCHEMBL7045650

SCHEMBL7045650

COc1nn(-c2ccc(NC(=O)OCc3ccccc3)cc2Cl)c(=O)o1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.61
FAAH O00519 3/20 0.61
PTGDR2 Q9Y5Y4 2/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44
ATM Q13315 1/20 0.44
SCD O00767 3/20 0.44
POLB P06746 1/20 0.42
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044232 0.90 MGLL (0.68) MGLLFAAHPTGDR2ALDH1A1MAPT
SCHEMBL7046273 0.79 FAAH (0.60) MGLLFAAHMEN1KMT2AMAPT
SCHEMBL7043147 0.77 MGLL (0.81) MGLLFAAHNPC1RAB9A
SCHEMBL7042914 0.76 MGLL (1.00) MGLLFAAHSMN1; SMN2NPC1RAB9A
SCHEMBL29499689 0.76 MGLL (1.00) MGLLFAAHSMN1; SMN2NPC1RAB9A
SCHEMBL14183670 0.75 POLB (0.67) MGLLMEN1KMT2ATDP1ALDH1A1
SCHEMBL7041440 0.74 FAAH (0.49) MGLLFAAHMEN1KMT2ATDP1
SCHEMBL7383453 0.73 MAPT (0.72) MGLLMEN1KMT2AALDH1A1MAPT
SCHEMBL12583048 0.72 NPC1 (0.62) MGLLPTGDR2MEN1KMT2AALDH1A1
SCHEMBL11618467 0.72 FAAH (0.55) MGLLFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885PTGDR2 49/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885PTGDR2 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.